Новейшие достижения и будущие возможности биомедицины

Gail H. Cassell, Ph.D., DSc (hon)

Dr. Cassell is a Visiting Professor in the Department of Global Health and Social Medicine, Harvard Medical School and Vice President of TB Drug Discovery of the not-for-profit Infectious Disease Research Institute in Seattle.  Dr. Cassell has recently retired as Vice President, Scientific Affairs and Distinguished Lilly Research Scholar for Infectious Diseases, Eli Lilly and Company in Indianapolis, Indiana.  In this capacity among other things, she was responsible for initiating and leading the not-for-profit Lilly TB Drug Discovery Initiative launched in 2007.  In 2003, she was one of two individuals at Lilly who initiated and developed the Lilly Multidrug Resistant Tuberculosis (MDRTB) Partnership.  The partnership has resulted in company support to date of $135 million dollars and is the largest philanthropic effort in Lilly’s 135 year history.   Prior to moving to Lilly in 1997, Dr. Cassell was the former Charles H. McCauley Professor and Chairman of the Department of Microbiology at the University of Alabama Schools of Medicine and Dentistry at Birmingham, a department which ranked first in research funding from the National Institutes of Health during the decade of her leadership.  She obtained her B.S. from the University of Alabama in Tuscaloosa and in 1993 was selected by that institution as one of the top 31 female graduates of the 20th century.  She obtained her Ph.D. in Microbiology from the University of Alabama at Birmingham and was selected as its 2003 Distinguished Alumnus. She is a past President of the American Society for Microbiology and past member of the Board of Scientific Councilors of the Center for Infectious Diseases, Centers for Disease Control and Prevention (CDC) and member of the CDC Director’s Advisory Committee;  Advisory Board of the Director of National Institutes of Health;  the Secretary of Health and Human Services Advisory Council of Public Health Preparedness and  the FDA Science Board,  Advisory  Board to the Commissioner. Currently she is a member of the NIH Science Management Board, the newly appointed “NIH board of Trustees” and the Advisory Council of the Fogarty International Center of NIH.  She has served on several editorial boards of scientific journals and has authored over 350 articles and book chapters.  Dr. Cassell has received national and international awards, including the CDC Honor Award in Public Health, a Citation from the FDA Commissioner and the Emmy Klineberger-Nobel Award by the International Organization for Mycoplasmology for outstanding and sustained research contributions, and two honorary degrees for her research in infectious diseases.   She is a member of the Institute of Medicine (IOM) of the National Academy of Sciences and has served two terms on the IOM Council, the governing board.   She was elected in 2011 to membership on the U.S Council of Foreign Relations.

She is an Emeritus Member of the Board of Research!America and a former member and Chair of the Board of Directors of the Burroughs Wellcome Fund.  She has recently completed  terms on the Leadership Council of the School of Public Health of Harvard University,  the Executive Committee of Columbia University Medical Center Board of Visitors, and the Johns Hopkins School of Nursing.  Currently she is a member of the Morehouse School of Medicine Board of Trustees, and the Advisory Council of the University of North Carolina Gillings School of Global Public Health.  

John Glass, PhD

Professorб Synthetic Biology Group, J. Craig Venter Institute

Email: jglass@jcvi.org

Dr. John Glass is a Professor in the J. Craig Venter Institute’s Synthetic Biology Group. He was one of the leaders of the team that built a synthetic bacterial cell. His expertise is in microbial pathogenesis, microbial genomics, and RNA virology. At the JCVI, Glass leads the mycoplasma minimal genome, genome transplantation, and influenza virus vaccine projects and has been a key scientist in, environmental genomics and viral metagenomics work. Glass is also an adjunct faculty member at the University of Maryland at College Park.

Prior to joining the Venter Institute Glass spent five years in the Infectious Diseases Research Division of the pharmaceutical company Eli Lilly, where he directed a hepatitis C virology group and a microbial genomics group (1998-2003).

Glass earned his undergraduate and graduate degrees from the University of North Carolina at Chapel Hill. His Ph.D. work was on RNA virus genetics in the laboratory of Gail Wertz. Pursuing vaccines based on recombinant vaccinia viruses, Glass did postdocs at the University of Alabama at Birmingham (UAB) in polio virology under Casey Morrow and mycoplasma pathogenesis under Gail Cassell. Later he joined the faculty in the UAB Microbiology and Immunology Department working on mycoplasma diagnostic methods based on genomic data. On sabbatical leave in Ellson Chen’s lab at Applied Biosystems Inc.(1995-1997) he sequenced the genome of Ureaplasma parvum and began his study mycoplasma genomics.

Andrew M. Dahlem, Ph.D.

Vice President, Chief Operating Officerб Lilly Research Laboratories (LRL), LRL-Europeб Eli Lilly and Company

Andrew M. Dahlem, Ph.D., was named vice president and chief operating officer for Lilly Research Laboratories (LRL) and LRL Europe in February 2007.  He has previously served as vice president of toxicology, drug disposition, pharmacokinetics, and Lilly Research Laboratories in Europe since January 2003 and a member of Lilly senior management.

Dr. Dahlem received a bachelor of science degree in wildlife biology from The Ohio State University in 1982 and a doctor of philosophy degree in toxicology from the University of Illinois at Urbana-Champaign in 1989. 

Dahlem joined Lilly in 1990 as a senior pharmacologist.  He became head of biochemical toxicology in 1992.  He was named director of drug disposition and biochemical (investigative) toxicology in 1993.  He was promoted to executive director for toxicology and drug disposition in 1998, and he assumed responsibility for LRL in Europe in 1999 and for discovery operations in 2000.  In December 2001 he was promoted to Vice President.

Dr. Dahlem serves as adjunct professor of toxicology in the College of Veterinary Medicine at Purdue University, the University of Illinois at Urbana-Champaign, and at The Ohio State University.  He is also a member of the Ohio State University College of Pharmacy Corporate Council and the Illinois Professional Science Master’s Board.

Dr. Dahlem currently serves on the board of directors for Indigo Biosystems, the YourEncore board of advisors, and is a member of the Indiana State Museum Foundation Board.  He is a member of the Institute of Medicine Forum on Drug Discovery, Development and Translation and the Translational Research and the Critical Path for Tuberculosis Drug Regimens for the Gates Foundation.

He is a member and past president of Indianapolis/Cincinnati Discussion Group of the American Association of Pharmaceutical Scientists.  He is also a member of the International Society for the Study of Xenobiotics, the Society of Toxicology, and the American Association for the Advancement of Science.

Roger I. Glass, M.D., Ph.D.

Director, Fogarty International Center, Associate Director for International Research, NIH, National Institutes of Health, Bethesda, Maryland, USA

Email: glassr@mail.nih.gov

Dr. Glass was named Director of the Fogarty International Center and Associate Director for International Research by NIH Director Elias A. Zerhouni, M.D., on March 31, 2006.

Dr. Glass graduated from Harvard College in 1967, received a Fulbright Fellowship to study at the University of Buenos Aires in 1967, and received his M.D. from Harvard Medical School and his M.P.H. from the Harvard School of Public Health in 1972. He joined the Centers for Disease Control and Prevention in 1977 as a medical officer assigned to the Environmental Hazards Branch. He was a Scientist at the International Center for Diarrheal Disease Research in Bangladesh from 1979-1983 and returned to Sweden where he received his doctorate from the University of Goteborg. In 1984, he joined the National Institutes of Health Laboratory of Infectious Diseases, where he worked on the molecular biology of rotavirus. In 1986, Dr. Glass returned to the CDC to become Chief of the Viral Gastroenteritis Unit at the National Center for Infectious Diseases.

Dr. Glass’s research interests are in the prevention of gastroenteritis from rotaviruses and noroviruses through the application of novel scientific research. He has maintained field studies in India, Bangladesh, Brazil, Mexico, Israel, Russia, Vietnam, China and elsewhere. His research has been targeted toward epidemiologic studies to anticipate the introduction of rotavirus vaccines. He is fluent and often lectures in five languages.    Dr. Glass is a member of the Institute of Medicine of the National Academies of Science.

Carole HEILMAN

NIAID, National Institute of Health, Division of Microbiology & Infectious Diseases

Email: Cheilman@niaid.nih.gov

Dr. Carole Heilman is the Director of the Division of Microbiology and Infectious Diseases (DMID), at the National Institute of Allergy and Infectious Diseases (NIAID), a component of the National Institutes of Health (NIH)/U.S. Department of Health and Human Services (DHHS).  As Director of DMID she has responsibility for scientific direction, oversight, and management of all extramural research programs on infectious diseases (except AIDS) within the NIH. In addition, since 2001 Dr. Heilman has played a critical role in launching and directing NIAID’s extramural biodefense research program.  Previously, Dr. Heilman served as Deputy Director of NIAID’s Division of AIDS for 3 years. Dr. Heilman has a Ph.D. in microbiology from Rutgers University.  She did her post-doctoral work in molecular virology at the National Cancer Institute and continued at the NCI as a senior staff fellow in molecular oncology.  She moved into health science administration in 1986, focusing on respiratory pathogens, particularly vaccine development.  She has received numerous awards for scientific management and leadership, including three DHHS Secretary’s Awards for Distinguished Service for her contributions to developing pertussis, biodefense and AIDS vaccines.

Marya Levintova, PhD

International Program Officer for Russia, Eurasia and Arctic Affairs

Fogarty International Center, National Institutes of Health

Email: Marya.Levintova@nih.gov

Dr. Levintova joined the Division of International Relations, Fogarty International Center, National Institutes of Health (NIH), in May 2006 with responsibilities covering Russia, Eurasia and the Arctic regions.  Prior to joining NIH in 2006, Dr. Levintova was a postdoctoral research fellow at the Alcohol Research Group, School of Public Health, University of Berkeley, where she analyzed the impact of alcohol control policies on alcohol consumption and mortality in the Russian Federation.  For about 5 years, Dr. Levintova has been examining health-related policies, legislation, and programs in the countries of the former Soviet Union, in particular focusing on non-communicable diseases.  Dr. Levintova is a recipient of the Fulbright Scholar award for the study of the impact of the demographic changes on health-related legislation and policies in the Russian Federation. 

Dr. Levintova immigrated to the United States from the Soviet Union in 1989.  She holds a Ph.D. in Clinical Psychology from Alliant University/California School of Professional Psychology, and a B.A. from the University of Redlands.  Her research interests include development and implementation of public health policies and legislation; tobacco, alcohol, and drug abuse control, and the interplay of multi-sectoral stakeholders in the policy decision-making process.  Dr. Levintova is fluent in Russian.

Richard Galbraith, MD, PhD

Professor of Medicine and Director of the Center for Clinical and Translational Science and Associate Dean for Patient Oriented Research at the University of Vermont College of Medicine

E-mail:  Richard.Galbraith@uvm.edu

Dr. Galbraith serves as the Director of the University of Vermont’s Center for Clinical and Translational Science.  The Center is dedicated to the concept of applying interdisciplinary research to translational science both from the bench to the bedside and from the bedside to the bench.  Much of this work is carried out in a dedicated state-of-the-art facility, the College of Medicine Clinical Research Center. 

Dr. Galbraith received his MD degree from King’s College University, London England and a PhD in Molecular and Cellular Physiology from the Medical University of South Carolina in the U.S.  He spent 12 years at the Rockefeller University Hospital in Manhattan, New York where he directed the Rockefeller University Hospital and its attendant translational research programs.  He has worked in basic, translational and clinical research and has published numerous papers and review articles.  Dr. Galbraith is a Fellow of the Royal College of Physicians, a member of the Vermont Academy of Science and Engineering and a member of the American Society for Clinical Investigation.  He chairs the Clinical Research Committee of the Federation of American Societies for Experimental Biology and chaired the recent symposium on “Engaging Basic Scientists in Translational Research”. He also serves on the Board of the Association of the Accreditation of Human Research Protection Programs.

Jennifer A. Hobin, PhD

Director of Science Policy at the Federation of American Societies for Experimental  Biology (FASEB)

Jennifer A. Hobin is the Director of Science Policy at the Federation of American Societies for Experimental Biology (FASEB). She directs the development of major reports, policy statements, and position papers and plays a key role in the strategic planning of FASEB’s science policy program. Dr. Hobin is also responsible for policy issues related to scientific training and career development, clinical and translational research, the protection of human research participants, and peer review. Prior to joining FASEB, Dr. Hobin was a Christine Mirzayan Science and Technology Policy Graduate Fellow at the National Academies’ Committee on Science, Engineering, and Public Policy, where she contributed to a report on maximizing the potential of women in academic science and engineering. She earned her doctorate in biopsychology from the University of Michigan by describing the neural circuits mediating the context-specific expression of Pavlovian fear memory. She has a BA in psychology, summa cum laude, from Stony Brook University. Dr. Hobin serves on the National Postdoctoral Association’s Advocacy Committee and is Past President of the Association for Women in Science, Washington, D.C. Metropolitan Chapter.

Joseph Michael Campos, PhD

Director of the Microbiology Laboratory, Molecular Diagnostics Laboratory, and Laboratory Informatics at Children’s National Medical Center

Professor, Departments of Pediatrics, Pathology, and Microbiology /Immunology/ Tropical Medicine at the George Washington University Medical Center

Email:  jcampos@childrensnational.org

Dr. Joseph Campos is the Director of the Microbiology Laboratory, the Molecular Diagnostics Laboratory and the Section of Laboratory Informatics at Children’s National Medical Center where he has worked since September 1985.  In these roles, Dr. Campos oversees the laboratory diagnosis and management of infectious diseases in children as well as the operation of the medical center’s laboratory information system.  Dr. Campos is also a tenured professor in the Departments of Pediatrics, Pathology, and Microbiology/Immunology/Tropical Medicine at the George Washington University Medical Center where he participates in the teaching of medical students, residents, and fellows. 

Dr. Campos received his AB, MA, and PhD in bacteriology from the University of California, Berkeley.  He studied as a postdoctoral fellow in clinical microbiology at the Temple University School of Medicine in Philadelphia PA.   He served as Director of the Microbiology Laboratory at the Children’s Hospital of Philadelphia from 1978-1985.  He is board-certified by the American Board of Medical Microbiology and is an elected Fellow of the American Academy of Microbiology.  He was the recipient of the American Academy of Microbiology bioMerieux-Sonnenwirth Award for Leadership in Clinical Microbiology and the American Academy of Microbiology Trek Diagnostics ABMM/ABMLI Professional Recognition Award.  He was elected the first Dean of the American College of Microbiology and served in that role for six years.  He was appointed to the Clinical Laboratory Improvement Advisory Committee (CLIAC) for four years and was Chair of the Laboratory Practices Committee of the American Society for Microbiology for four years.  He currently is serving his fifth year in the elected position of Secretary of the American Society for Microbiology.  He has authored more than 130 scientific papers and book chapters and delivered almost 500 invited lectures around the world.  

Dr. Jason Rao, Director, International Affairs American Society for Microbiology

Dr. Jason Rao is currently the Director of International Affairs at the American Society for Microbiology, where he oversees global outreach to more than 40,000 members. Dr Rao recently served as Senior Policy Advisor for Global Science Engagement in the White House Office of Science and Technology Policy, where his responsibilities include President Obama’s Global Engagement initiative, aimed at renewing science and technology partnerships to meet grand challenges around the globe.

Dr. Rao previously served in the U.S. Department of State for nearly a decade, where he was responsible for a range of foreign assistance programs aimed at enhancing scientist engagement as well as global health security. During that time Dr. Rao created and launched two novel initiatives, the BioIndustry Initiative in Russia, forging public-private partnerships to accelerate drug and vaccine development for emerging infectious diseases, as well as the Bio Engagement Program (BEP) in South and South East Asia, the Middle East, North Africa and Latin America, which focused on innovation, collaborative R&D networks and capacity building.

During his time with the State Department, Dr. Rao lived in both Indonesia and Pakistan. He served as the Advisor for Health Security at U.S. Embassy Islamabad, and was instrumental in building the U.S.-Pakistan S&T collaborative framework, as well as breaking new ground on a range of partnership and outreach initiatives in the region.

In 2009 Dr. Rao became a Brookings Legislative Fellow in the 111th Congress, working with both the Senate Foreign Relations and Homeland Security and Government Affairs Committees, contributing to new legislation on international science cooperation.

Dr. Rao began his career in government as an American Association for the Advancement of Science Diplomacy Fellow; before coming to government, he worked as a scientist in the pharmaceutical industry and as a research fellow at the National Institutes of Health. Dr. Rao holds a Ph.D. in Biochemistry, Cellular and Molecular Biology from the Johns Hopkins University School of Medicine and earned his bachelor’s degree in synthetic organic chemistry from the University of California at Santa Cruz. He currently lectures at Georgetown University and the George Washington University.